- Home
- GPCR vs GLPG Comparison
GPCR vs GLPG Comparison
Compare GPCR & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GPCR
- GLPG
- Stock Information
- Founded
- GPCR 2016
- GLPG 1999
- Country
- GPCR United States
- GLPG Belgium
- Employees
- GPCR N/A
- GLPG N/A
- Industry
- GPCR
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- GPCR
- GLPG Health Care
- Exchange
- GPCR Nasdaq
- GLPG Nasdaq
- Market Cap
- GPCR 1.6B
- GLPG 1.8B
- IPO Year
- GPCR 2023
- GLPG 2005
- Fundamental
- Price
- GPCR $23.77
- GLPG $26.74
- Analyst Decision
- GPCR Strong Buy
- GLPG Sell
- Analyst Count
- GPCR 7
- GLPG 5
- Target Price
- GPCR $81.29
- GLPG $26.75
- AVG Volume (30 Days)
- GPCR 752.3K
- GLPG 355.9K
- Earning Date
- GPCR 03-07-2025
- GLPG 02-12-2025
- Dividend Yield
- GPCR N/A
- GLPG N/A
- EPS Growth
- GPCR N/A
- GLPG N/A
- EPS
- GPCR N/A
- GLPG 1.16
- Revenue
- GPCR N/A
- GLPG $285,380,474.00
- Revenue This Year
- GPCR N/A
- GLPG $2.78
- Revenue Next Year
- GPCR N/A
- GLPG $1.62
- P/E Ratio
- GPCR N/A
- GLPG $23.02
- Revenue Growth
- GPCR N/A
- GLPG 14.99
- 52 Week Low
- GPCR $22.33
- GLPG $22.36
- 52 Week High
- GPCR $62.74
- GLPG $37.22
- Technical
- Relative Strength Index (RSI)
- GPCR 37.89
- GLPG 71.20
- Support Level
- GPCR $22.33
- GLPG $26.49
- Resistance Level
- GPCR $25.17
- GLPG $27.48
- Average True Range (ATR)
- GPCR 1.73
- GLPG 0.66
- MACD
- GPCR -0.37
- GLPG 0.54
- Stochastic Oscillator
- GPCR 15.94
- GLPG 85.55
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.